I. Hengrui Medicine (600276), the first stock of domestic innovative drugs. The main product lines are anti-tumor, anesthesia, contrast agents and so on. The company's net
return on assets for many years to maintain more than 23%, net profit for many years to maintain a rate of growth of more than 20%. The company's R&D strength is very strong,
the management team is relatively good, and the sales capacity is also very strong.
Second, Aier Ophthalmology (300015), the first share of the domestic ophthalmic hospital chain. Mainly to provide patients with a variety of ophthalmic diseases diagnosis, treatmentand medical optometry and other ophthalmic medical services. The company's return on net assets for many years to maintain at about 20%, net profit for many years to maintain 30%
more than the rate of growth. The company's business model is relatively excellent, and its operating ability and brand reputation continue to grow.?
Three, Myriad Medical (300760), the first domestic medical device stocks. The main product lines are life and information support, in vitro diagnostics, medical
imaging and so on. The company's return on net assets for many years to maintain more than 25%, net profit for many years to maintain a rate of growth of more than 25%. The company as
for the completion of the globalization of the layout of the leading medical devices, high-end, platform steadily advancing, the position is very solid, the long-term space is huge.?
Four, Changchun High-tech (000661), the first domestic biopharmaceutical stocks. The main product lines are growth hormone, syncytial virus vaccine. The company
the return on net assets for many years to maintain more than 16%, net profit for many years to maintain a rate of growth of more than 30%. The company as China's leading biomedical
pharmaceuticals, performance exceeded the expected growth.
V. WuXi AppTec (603259), the first domestic medical research and development services. The main business is the discovery of small molecule chemical drugs, research and development and productionproduction of a full range of integrated platform services. The company's return on net assets has remained above 20% for many years, and its net profit has maintained a growth rate of over 25% for many years
. The company is the world's leading pharmaceutical R & D service platform, the market space is broad, performance is expected to maintain rapid growth.
Six, Tigermed (300347), the country's leading clinical contract research organization (CRO) leader. The main business is for pharmaceutical product development
Provide Ⅰ to Ⅳ phase clinical trial technical services, data management and other clinical research services. The company's return on net assets has improved to around 17% in the past two years
and its net profit has maintained a growth rate of over 56% over the years.?
Seven, I Wu biology (300357), the first domestic desensitization diagnosis and treatment shares. The company's dust mite drops to maintain high growth, the heavyweight product Huanghua
Artemisia pollen sublingual drops into the site verification, is expected to be approved for listing in 2020. The company's return on net assets has remained above 21% for many years
and its net profit has maintained a growth rate of over 25% for many years. The company as China's only sublingual desensitization leading enterprises, the competitive landscape
extremely good, market share of more than 80%, the company's long-term growth potential.?
Eight, Tongze medical (600763), the first domestic oral chain shares. The company through the "hospital can be copied + doctors can be copied + team can be copied"
model, to start the layout of the dental hospital chain. The company's return on net assets has been maintained at about 23% for many years, and the net profit has been maintained at about 50% for many years
right growth rate. China's oral market space is vast, the company is expected to get fast
fast development under the two major trends of population aging and consumption upgrading.
Nine, AnTuBio (603658), the domestic IVD leading stock. The company is mainly engaged in the in vitro diagnostic reagents and its supporting instrumentation research and development, production
and sales. The company's return on net assets for many years to maintain at about 30%, net profit for many years to maintain a rate of growth of more than 25%. Chemical hair
Light industry will enter the era of differentiation. The company with 70% biological raw material assets, mainstream projects, assembly lines and other advantages, is expected to continue to replace
foreign and other domestic products, to maintain sustained growth.?
Ten, Hualan Bio (002007), the leading stock of domestic blood products. The company's main product lines are blood products and vaccine products. The company's
return on net assets for many years to maintain at about 19%, net profit for many years to maintain a rate of growth of about 30%. With the slow
slow recovery of the domestic blood products industry and the continued release of influenza vaccines, the company's performance is expected to be further improved.